| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Medicare | 103 | 2023 | 332 | 15.040 |
Why?
|
| Nursing Homes | 24 | 2025 | 64 | 8.670 |
Why?
|
| Aged | 240 | 2025 | 8214 | 7.730 |
Why?
|
| Aged, 80 and over | 160 | 2025 | 2853 | 7.700 |
Why?
|
| United States | 165 | 2025 | 5205 | 6.740 |
Why?
|
| Hospitalists | 15 | 2021 | 17 | 6.160 |
Why?
|
| Hospitalization | 29 | 2022 | 485 | 6.100 |
Why?
|
| Patient Discharge | 20 | 2023 | 128 | 5.090 |
Why?
|
| Retrospective Studies | 88 | 2024 | 2544 | 4.990 |
Why?
|
| Humans | 300 | 2025 | 43102 | 4.180 |
Why?
|
| Early Detection of Cancer | 16 | 2025 | 449 | 4.040 |
Why?
|
| Female | 216 | 2025 | 24698 | 3.910 |
Why?
|
| Lung Neoplasms | 15 | 2023 | 495 | 3.900 |
Why?
|
| Male | 197 | 2025 | 23409 | 3.820 |
Why?
|
| Long-Term Care | 8 | 2021 | 55 | 3.680 |
Why?
|
| Homes for the Aged | 8 | 2025 | 19 | 3.600 |
Why?
|
| Continuity of Patient Care | 13 | 2021 | 120 | 3.580 |
Why?
|
| Length of Stay | 20 | 2021 | 229 | 3.570 |
Why?
|
| Breast Neoplasms | 38 | 2025 | 1723 | 3.520 |
Why?
|
| Texas | 44 | 2021 | 457 | 3.420 |
Why?
|
| Primary Health Care | 16 | 2024 | 380 | 3.400 |
Why?
|
| Patient Readmission | 17 | 2023 | 122 | 3.350 |
Why?
|
| Mexican Americans | 19 | 2012 | 226 | 3.270 |
Why?
|
| Cohort Studies | 50 | 2025 | 1759 | 3.170 |
Why?
|
| Skilled Nursing Facilities | 11 | 2023 | 20 | 3.110 |
Why?
|
| Analgesics, Opioid | 8 | 2021 | 252 | 2.980 |
Why?
|
| Mass Screening | 16 | 2025 | 541 | 2.960 |
Why?
|
| Drug Prescriptions | 9 | 2020 | 60 | 2.830 |
Why?
|
| SEER Program | 41 | 2016 | 164 | 2.790 |
Why?
|
| Mammography | 12 | 2025 | 212 | 2.770 |
Why?
|
| Nurse Practitioners | 8 | 2021 | 24 | 2.760 |
Why?
|
| Hospitals | 9 | 2021 | 117 | 2.720 |
Why?
|
| Mortality | 9 | 2022 | 175 | 2.560 |
Why?
|
| Life Expectancy | 10 | 2017 | 72 | 2.430 |
Why?
|
| Prostatic Neoplasms | 17 | 2016 | 1092 | 2.410 |
Why?
|
| Prostate-Specific Antigen | 6 | 2016 | 147 | 2.360 |
Why?
|
| Visitors to Patients | 4 | 2025 | 4 | 2.310 |
Why?
|
| Emergency Service, Hospital | 8 | 2017 | 278 | 2.280 |
Why?
|
| Diphosphonates | 6 | 2017 | 19 | 2.260 |
Why?
|
| Medicare Part D | 7 | 2021 | 12 | 2.220 |
Why?
|
| Comorbidity | 21 | 2022 | 737 | 2.200 |
Why?
|
| Dementia | 8 | 2021 | 160 | 2.040 |
Why?
|
| Physicians | 5 | 2021 | 188 | 1.860 |
Why?
|
| Colorectal Neoplasms | 11 | 2014 | 512 | 1.850 |
Why?
|
| Middle Aged | 64 | 2021 | 12222 | 1.780 |
Why?
|
| Ambulatory Care | 6 | 2021 | 81 | 1.710 |
Why?
|
| Colonoscopy | 7 | 2013 | 122 | 1.690 |
Why?
|
| Health Services Misuse | 5 | 2015 | 20 | 1.630 |
Why?
|
| Drug Utilization | 4 | 2021 | 34 | 1.570 |
Why?
|
| Risk Factors | 38 | 2021 | 3994 | 1.550 |
Why?
|
| Referral and Consultation | 6 | 2015 | 142 | 1.530 |
Why?
|
| Patient Care Team | 5 | 2019 | 60 | 1.520 |
Why?
|
| Hypoglycemia | 4 | 2017 | 24 | 1.520 |
Why?
|
| Neoplasms | 13 | 2018 | 1377 | 1.510 |
Why?
|
| Diabetes Mellitus | 10 | 2024 | 539 | 1.490 |
Why?
|
| Anticoagulants | 3 | 2024 | 122 | 1.480 |
Why?
|
| Stroke | 10 | 2019 | 340 | 1.480 |
Why?
|
| Inpatients | 4 | 2021 | 78 | 1.470 |
Why?
|
| Health Services Accessibility | 13 | 2014 | 706 | 1.470 |
Why?
|
| Logistic Models | 27 | 2021 | 1009 | 1.460 |
Why?
|
| Proportional Hazards Models | 24 | 2017 | 518 | 1.440 |
Why?
|
| Medicaid | 5 | 2025 | 143 | 1.430 |
Why?
|
| Risk Assessment | 16 | 2022 | 863 | 1.400 |
Why?
|
| Healthcare Disparities | 6 | 2025 | 590 | 1.390 |
Why?
|
| Hypoglycemic Agents | 4 | 2017 | 184 | 1.380 |
Why?
|
| Aging | 13 | 2017 | 783 | 1.350 |
Why?
|
| Walking | 7 | 2013 | 88 | 1.290 |
Why?
|
| Activities of Daily Living | 17 | 2021 | 139 | 1.280 |
Why?
|
| Age Factors | 27 | 2018 | 1154 | 1.280 |
Why?
|
| Cholecystectomy | 4 | 2014 | 14 | 1.270 |
Why?
|
| Personnel Staffing and Scheduling | 2 | 2020 | 14 | 1.230 |
Why?
|
| Hypertension | 7 | 2024 | 835 | 1.230 |
Why?
|
| Bone Density Conservation Agents | 5 | 2017 | 28 | 1.220 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2019 | 245 | 1.220 |
Why?
|
| Residence Characteristics | 7 | 2021 | 363 | 1.220 |
Why?
|
| Socioeconomic Factors | 24 | 2022 | 1234 | 1.210 |
Why?
|
| Multivariate Analysis | 26 | 2016 | 638 | 1.210 |
Why?
|
| Hospice Care | 5 | 2010 | 20 | 1.210 |
Why?
|
| Warfarin | 2 | 2024 | 67 | 1.200 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 4 | 2021 | 59 | 1.180 |
Why?
|
| Electronic Health Records | 4 | 2017 | 108 | 1.170 |
Why?
|
| Hospital Mortality | 8 | 2022 | 210 | 1.140 |
Why?
|
| Adenocarcinoma | 9 | 2013 | 291 | 1.130 |
Why?
|
| Patient Care | 2 | 2024 | 31 | 1.120 |
Why?
|
| Hydrocodone | 2 | 2018 | 4 | 1.120 |
Why?
|
| Health Care Costs | 4 | 2020 | 91 | 1.110 |
Why?
|
| Geriatric Assessment | 11 | 2013 | 66 | 1.100 |
Why?
|
| Follow-Up Studies | 16 | 2024 | 1067 | 1.080 |
Why?
|
| Epistaxis | 2 | 2017 | 2 | 1.060 |
Why?
|
| Androgen Antagonists | 5 | 2008 | 29 | 1.050 |
Why?
|
| Pancreatectomy | 5 | 2011 | 10 | 1.050 |
Why?
|
| Cross-Sectional Studies | 18 | 2021 | 3156 | 1.010 |
Why?
|
| Postoperative Complications | 5 | 2020 | 263 | 1.010 |
Why?
|
| Health Policy | 5 | 2025 | 184 | 1.010 |
Why?
|
| Survival Rate | 16 | 2018 | 355 | 1.000 |
Why?
|
| Patient Participation | 4 | 2020 | 94 | 0.990 |
Why?
|
| Colonic Neoplasms | 4 | 2011 | 223 | 0.990 |
Why?
|
| Pancreatic Neoplasms | 9 | 2013 | 218 | 0.990 |
Why?
|
| Gallstones | 4 | 2015 | 8 | 0.980 |
Why?
|
| Patient Admission | 3 | 2017 | 50 | 0.980 |
Why?
|
| Time Factors | 22 | 2020 | 1857 | 0.970 |
Why?
|
| Osteonecrosis | 3 | 2017 | 8 | 0.960 |
Why?
|
| Terminal Care | 3 | 2013 | 54 | 0.950 |
Why?
|
| Adult | 39 | 2021 | 13872 | 0.940 |
Why?
|
| Neoplasm Staging | 18 | 2014 | 374 | 0.940 |
Why?
|
| Cell Membrane | 6 | 2021 | 403 | 0.920 |
Why?
|
| Hospital Costs | 2 | 2018 | 27 | 0.900 |
Why?
|
| Odds Ratio | 14 | 2021 | 587 | 0.890 |
Why?
|
| Kallikreins | 2 | 2016 | 11 | 0.880 |
Why?
|
| Hospices | 2 | 2023 | 5 | 0.870 |
Why?
|
| Quality of Life | 6 | 2024 | 616 | 0.860 |
Why?
|
| Cholinergic Antagonists | 2 | 2021 | 10 | 0.840 |
Why?
|
| Osteoporosis | 2 | 2016 | 45 | 0.840 |
Why?
|
| Survival Analysis | 14 | 2018 | 368 | 0.840 |
Why?
|
| Gonadotropin-Releasing Hormone | 5 | 2008 | 39 | 0.830 |
Why?
|
| Developing Countries | 2 | 2024 | 113 | 0.830 |
Why?
|
| Opioid-Related Disorders | 4 | 2019 | 195 | 0.820 |
Why?
|
| Chemotherapy, Adjuvant | 8 | 2012 | 53 | 0.820 |
Why?
|
| Dopamine | 5 | 2021 | 275 | 0.820 |
Why?
|
| Anti-Infective Agents | 2 | 2014 | 75 | 0.810 |
Why?
|
| Severity of Illness Index | 5 | 2021 | 719 | 0.810 |
Why?
|
| Patient Acceptance of Health Care | 4 | 2018 | 497 | 0.810 |
Why?
|
| International Classification of Diseases | 2 | 2022 | 27 | 0.800 |
Why?
|
| Mental Disorders | 2 | 2022 | 392 | 0.800 |
Why?
|
| Health Services for the Aged | 7 | 2012 | 26 | 0.780 |
Why?
|
| Quality Indicators, Health Care | 4 | 2021 | 49 | 0.780 |
Why?
|
| Treatment Outcome | 15 | 2024 | 1604 | 0.770 |
Why?
|
| Arthroplasty, Replacement, Hip | 4 | 2021 | 21 | 0.760 |
Why?
|
| Benzodiazepines | 2 | 2021 | 21 | 0.760 |
Why?
|
| Jaw Diseases | 3 | 2017 | 4 | 0.760 |
Why?
|
| Sex Factors | 12 | 2021 | 1028 | 0.760 |
Why?
|
| Androgens | 3 | 2016 | 106 | 0.760 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2010 | 133 | 0.760 |
Why?
|
| Prognosis | 12 | 2018 | 861 | 0.750 |
Why?
|
| Osteoarthritis | 3 | 2007 | 25 | 0.750 |
Why?
|
| Geriatrics | 5 | 2010 | 67 | 0.750 |
Why?
|
| Cause of Death | 8 | 2014 | 186 | 0.740 |
Why?
|
| Hip Fractures | 6 | 2018 | 29 | 0.740 |
Why?
|
| Clinical Competence | 2 | 2014 | 156 | 0.740 |
Why?
|
| Disability Evaluation | 7 | 2017 | 73 | 0.730 |
Why?
|
| Acculturation | 5 | 2012 | 205 | 0.720 |
Why?
|
| Depression | 8 | 2021 | 863 | 0.720 |
Why?
|
| Risk Adjustment | 2 | 2019 | 18 | 0.710 |
Why?
|
| Positron-Emission Tomography | 2 | 2019 | 93 | 0.710 |
Why?
|
| Biopsy | 3 | 2019 | 177 | 0.710 |
Why?
|
| Herpes Simplex | 2 | 2012 | 19 | 0.690 |
Why?
|
| Respiratory Tract Diseases | 2 | 2015 | 31 | 0.690 |
Why?
|
| ras Proteins | 3 | 2005 | 54 | 0.680 |
Why?
|
| Motivation | 1 | 2025 | 513 | 0.680 |
Why?
|
| Delivery of Health Care | 3 | 2019 | 310 | 0.670 |
Why?
|
| Herpesvirus 1, Human | 2 | 2012 | 64 | 0.670 |
Why?
|
| Alzheimer Disease | 3 | 2025 | 1001 | 0.650 |
Why?
|
| Antihypertensive Agents | 3 | 2012 | 287 | 0.650 |
Why?
|
| Chronic Disease | 6 | 2018 | 549 | 0.640 |
Why?
|
| Atrial Fibrillation | 2 | 2013 | 122 | 0.640 |
Why?
|
| Incidence | 13 | 2016 | 1078 | 0.640 |
Why?
|
| Professional-Patient Relations | 1 | 2020 | 60 | 0.640 |
Why?
|
| Testosterone | 2 | 2018 | 211 | 0.630 |
Why?
|
| Insurance, Disability | 1 | 2019 | 2 | 0.630 |
Why?
|
| Health Status Indicators | 2 | 2018 | 90 | 0.630 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 94 | 0.630 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2019 | 4 | 0.620 |
Why?
|
| Bronchoscopy | 1 | 2019 | 7 | 0.620 |
Why?
|
| Practice Guidelines as Topic | 7 | 2015 | 223 | 0.610 |
Why?
|
| Internal Medicine | 2 | 2010 | 32 | 0.610 |
Why?
|
| Surgical Procedures, Operative | 1 | 2019 | 33 | 0.610 |
Why?
|
| Guidelines as Topic | 1 | 2019 | 56 | 0.600 |
Why?
|
| Arthroplasty, Replacement, Knee | 3 | 2020 | 14 | 0.600 |
Why?
|
| Taxoids | 2 | 2012 | 50 | 0.600 |
Why?
|
| Health Services Research | 7 | 2013 | 161 | 0.600 |
Why?
|
| Tobacco Use Cessation | 1 | 2019 | 19 | 0.590 |
Why?
|
| Orchiectomy | 4 | 2007 | 37 | 0.590 |
Why?
|
| Appointments and Schedules | 1 | 2019 | 32 | 0.590 |
Why?
|
| Micronutrients | 2 | 2009 | 45 | 0.580 |
Why?
|
| Registries | 9 | 2009 | 437 | 0.580 |
Why?
|
| Medical Oncology | 3 | 2007 | 50 | 0.570 |
Why?
|
| Subacute Care | 4 | 2019 | 8 | 0.570 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2012 | 220 | 0.570 |
Why?
|
| Heart Failure | 3 | 2017 | 302 | 0.570 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2019 | 587 | 0.570 |
Why?
|
| Self Care | 6 | 2016 | 175 | 0.570 |
Why?
|
| Counseling | 1 | 2019 | 138 | 0.560 |
Why?
|
| Health Status | 9 | 2018 | 442 | 0.560 |
Why?
|
| Emigrants and Immigrants | 2 | 2012 | 158 | 0.560 |
Why?
|
| Mobility Limitation | 4 | 2017 | 21 | 0.550 |
Why?
|
| Intensive Care Units | 2 | 2009 | 72 | 0.550 |
Why?
|
| Drug and Narcotic Control | 1 | 2017 | 12 | 0.550 |
Why?
|
| Politics | 1 | 2018 | 42 | 0.550 |
Why?
|
| Uterine Cervical Neoplasms | 3 | 2014 | 367 | 0.540 |
Why?
|
| Fee-for-Service Plans | 5 | 2019 | 21 | 0.530 |
Why?
|
| Terminology as Topic | 2 | 2011 | 42 | 0.530 |
Why?
|
| Marital Status | 3 | 2011 | 46 | 0.520 |
Why?
|
| Hormone Replacement Therapy | 2 | 2016 | 49 | 0.520 |
Why?
|
| Cardiovascular Diseases | 5 | 2008 | 749 | 0.520 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2017 | 57 | 0.520 |
Why?
|
| Community Health Services | 3 | 2017 | 206 | 0.510 |
Why?
|
| Patient-Centered Care | 2 | 2015 | 75 | 0.510 |
Why?
|
| Databases, Factual | 5 | 2019 | 341 | 0.510 |
Why?
|
| CA-125 Antigen | 1 | 2016 | 11 | 0.510 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2017 | 375 | 0.510 |
Why?
|
| Cholangiography | 2 | 2013 | 4 | 0.500 |
Why?
|
| Survivors | 2 | 2017 | 152 | 0.500 |
Why?
|
| Emigration and Immigration | 2 | 2007 | 85 | 0.500 |
Why?
|
| Unnecessary Procedures | 2 | 2013 | 12 | 0.490 |
Why?
|
| Fluorescence Recovery After Photobleaching | 3 | 2011 | 9 | 0.490 |
Why?
|
| Radiotherapy | 2 | 2014 | 21 | 0.490 |
Why?
|
| Cognition | 6 | 2017 | 473 | 0.480 |
Why?
|
| Professional Practice | 1 | 2015 | 6 | 0.470 |
Why?
|
| Guideline Adherence | 4 | 2013 | 98 | 0.470 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 2 | 2007 | 65 | 0.470 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 3 | 2015 | 167 | 0.460 |
Why?
|
| Health Services | 2 | 2006 | 61 | 0.460 |
Why?
|
| Blood Pressure | 3 | 2018 | 666 | 0.460 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2006 | 47 | 0.450 |
Why?
|
| Insurance Claim Review | 7 | 2022 | 37 | 0.450 |
Why?
|
| Physician Assistants | 3 | 2020 | 20 | 0.450 |
Why?
|
| Diagnostic Imaging | 1 | 2015 | 53 | 0.450 |
Why?
|
| Anthracyclines | 2 | 2012 | 8 | 0.440 |
Why?
|
| Cytomegalovirus Infections | 2 | 2012 | 28 | 0.440 |
Why?
|
| Sulfonylurea Compounds | 1 | 2014 | 17 | 0.440 |
Why?
|
| Heart Diseases | 2 | 2014 | 112 | 0.430 |
Why?
|
| Advisory Committees | 1 | 2014 | 35 | 0.430 |
Why?
|
| Prospective Studies | 12 | 2013 | 1600 | 0.430 |
Why?
|
| Melanoma | 4 | 2011 | 110 | 0.430 |
Why?
|
| Neoplasms, Second Primary | 1 | 2014 | 15 | 0.420 |
Why?
|
| Patient Satisfaction | 4 | 2024 | 165 | 0.420 |
Why?
|
| Family | 2 | 2015 | 195 | 0.420 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2016 | 154 | 0.420 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2017 | 760 | 0.410 |
Why?
|
| Low Back Pain | 1 | 2015 | 101 | 0.410 |
Why?
|
| Body Mass Index | 6 | 2021 | 925 | 0.410 |
Why?
|
| Cholecystitis | 1 | 2013 | 7 | 0.410 |
Why?
|
| Bile Ducts | 1 | 2013 | 4 | 0.410 |
Why?
|
| Death Certificates | 3 | 2010 | 15 | 0.410 |
Why?
|
| Hand Strength | 2 | 2005 | 40 | 0.410 |
Why?
|
| Skin Neoplasms | 4 | 2011 | 178 | 0.410 |
Why?
|
| Antineoplastic Agents | 5 | 2017 | 1019 | 0.410 |
Why?
|
| State Health Plans | 1 | 2013 | 2 | 0.410 |
Why?
|
| Intraoperative Complications | 1 | 2013 | 20 | 0.400 |
Why?
|
| Cognition Disorders | 3 | 2012 | 243 | 0.400 |
Why?
|
| Diffusion of Innovation | 2 | 2013 | 38 | 0.400 |
Why?
|
| Longitudinal Studies | 7 | 2023 | 1063 | 0.400 |
Why?
|
| Social Class | 8 | 2013 | 291 | 0.400 |
Why?
|
| Health Resources | 2 | 2014 | 37 | 0.400 |
Why?
|
| Substance-Related Disorders | 1 | 2021 | 830 | 0.390 |
Why?
|
| Rehabilitation Centers | 2 | 2019 | 10 | 0.390 |
Why?
|
| Preventive Health Services | 1 | 2013 | 66 | 0.390 |
Why?
|
| Virus Activation | 1 | 2012 | 38 | 0.380 |
Why?
|
| Microscopy, Confocal | 7 | 2014 | 224 | 0.370 |
Why?
|
| Epstein-Barr Virus Infections | 2 | 2009 | 20 | 0.370 |
Why?
|
| Decision Making | 5 | 2018 | 249 | 0.370 |
Why?
|
| Ovarian Neoplasms | 1 | 2016 | 415 | 0.370 |
Why?
|
| Alcoholic Intoxication | 1 | 2012 | 21 | 0.370 |
Why?
|
| Seasons | 2 | 2016 | 139 | 0.360 |
Why?
|
| Physical Fitness | 1 | 2012 | 90 | 0.360 |
Why?
|
| Reproducibility of Results | 6 | 2019 | 1081 | 0.360 |
Why?
|
| Burial | 1 | 2011 | 3 | 0.360 |
Why?
|
| Grief | 1 | 2011 | 7 | 0.360 |
Why?
|
| Health Personnel | 2 | 2018 | 277 | 0.360 |
Why?
|
| Antibodies, Viral | 3 | 2012 | 306 | 0.350 |
Why?
|
| Neoplasms, Hormone-Dependent | 2 | 2008 | 19 | 0.350 |
Why?
|
| Accidental Falls | 1 | 2011 | 33 | 0.350 |
Why?
|
| Southwestern United States | 6 | 2007 | 47 | 0.350 |
Why?
|
| Family Practice | 2 | 2010 | 60 | 0.350 |
Why?
|
| Physician-Patient Relations | 5 | 2021 | 148 | 0.340 |
Why?
|
| Quality of Health Care | 4 | 2013 | 161 | 0.340 |
Why?
|
| Blood Chemical Analysis | 1 | 2011 | 25 | 0.340 |
Why?
|
| State Medicine | 2 | 2007 | 8 | 0.340 |
Why?
|
| Exercise | 1 | 2017 | 692 | 0.340 |
Why?
|
| Urology | 2 | 2007 | 9 | 0.340 |
Why?
|
| Health Promotion | 1 | 2017 | 704 | 0.330 |
Why?
|
| Thromboembolism | 1 | 2010 | 20 | 0.330 |
Why?
|
| Outpatients | 1 | 2010 | 37 | 0.330 |
Why?
|
| Professional Competence | 1 | 2010 | 42 | 0.330 |
Why?
|
| Administration, Oral | 2 | 2024 | 260 | 0.330 |
Why?
|
| Cholecystitis, Acute | 1 | 2010 | 5 | 0.330 |
Why?
|
| Educational Status | 6 | 2019 | 339 | 0.320 |
Why?
|
| California | 6 | 2009 | 548 | 0.320 |
Why?
|
| Porphyromonas gingivalis | 3 | 2015 | 40 | 0.320 |
Why?
|
| Amphetamine | 2 | 2015 | 21 | 0.320 |
Why?
|
| Medication Adherence | 1 | 2012 | 182 | 0.320 |
Why?
|
| Perioperative Care | 1 | 2010 | 11 | 0.320 |
Why?
|
| Suicide | 1 | 2011 | 140 | 0.310 |
Why?
|
| Prevalence | 7 | 2019 | 1612 | 0.310 |
Why?
|
| Virus Latency | 1 | 2009 | 49 | 0.310 |
Why?
|
| Interviews as Topic | 4 | 2018 | 452 | 0.300 |
Why?
|
| Allostasis | 1 | 2009 | 25 | 0.300 |
Why?
|
| Regression Analysis | 5 | 2013 | 490 | 0.300 |
Why?
|
| Insurance, Health | 4 | 2018 | 145 | 0.300 |
Why?
|
| Physicians, Family | 1 | 2009 | 29 | 0.300 |
Why?
|
| Resuscitation Orders | 1 | 2009 | 7 | 0.300 |
Why?
|
| Lipids | 1 | 2011 | 256 | 0.300 |
Why?
|
| Propensity Score | 5 | 2017 | 59 | 0.300 |
Why?
|
| Evidence-Based Medicine | 4 | 2013 | 107 | 0.290 |
Why?
|
| Ohio | 2 | 2025 | 18 | 0.290 |
Why?
|
| Physician's Role | 2 | 2006 | 40 | 0.290 |
Why?
|
| Education, Medical | 2 | 2007 | 118 | 0.290 |
Why?
|
| Pancreatic Diseases | 1 | 2008 | 6 | 0.290 |
Why?
|
| State Government | 2 | 2025 | 21 | 0.290 |
Why?
|
| Drug Interactions | 3 | 2014 | 150 | 0.290 |
Why?
|
| Demography | 4 | 2016 | 195 | 0.290 |
Why?
|
| Chemical Industry | 1 | 2008 | 2 | 0.290 |
Why?
|
| Attitude to Death | 2 | 2006 | 23 | 0.290 |
Why?
|
| Explosions | 1 | 2008 | 6 | 0.290 |
Why?
|
| Fractures, Bone | 2 | 2008 | 63 | 0.280 |
Why?
|
| Multilevel Analysis | 2 | 2018 | 21 | 0.280 |
Why?
|
| Cell Adhesion | 2 | 2014 | 238 | 0.280 |
Why?
|
| Environmental Pollution | 1 | 2008 | 27 | 0.280 |
Why?
|
| Drug-Eluting Stents | 1 | 2008 | 30 | 0.280 |
Why?
|
| Diabetes Complications | 3 | 2012 | 102 | 0.280 |
Why?
|
| Weight Loss | 2 | 2023 | 137 | 0.280 |
Why?
|
| Anxiety | 2 | 2006 | 874 | 0.280 |
Why?
|
| Adolescent | 11 | 2012 | 6081 | 0.270 |
Why?
|
| Stents | 1 | 2008 | 67 | 0.270 |
Why?
|
| Risk | 4 | 2013 | 287 | 0.270 |
Why?
|
| Patient Transfer | 2 | 2018 | 25 | 0.270 |
Why?
|
| Bone Neoplasms | 1 | 2008 | 49 | 0.270 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2007 | 6 | 0.270 |
Why?
|
| Regional Health Planning | 1 | 2007 | 14 | 0.270 |
Why?
|
| Nurse's Role | 2 | 2007 | 37 | 0.270 |
Why?
|
| Exosomes | 2 | 2014 | 126 | 0.270 |
Why?
|
| Oscillometry | 1 | 2007 | 9 | 0.260 |
Why?
|
| Metals | 1 | 2008 | 114 | 0.260 |
Why?
|
| Predictive Value of Tests | 6 | 2016 | 440 | 0.260 |
Why?
|
| Marketing of Health Services | 1 | 2007 | 8 | 0.260 |
Why?
|
| Wheelchairs | 1 | 2007 | 5 | 0.260 |
Why?
|
| Fraud | 1 | 2007 | 9 | 0.260 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2007 | 58 | 0.260 |
Why?
|
| Hypothermia | 1 | 2007 | 13 | 0.260 |
Why?
|
| Social Security | 1 | 2006 | 2 | 0.260 |
Why?
|
| Public Health Informatics | 1 | 2006 | 9 | 0.260 |
Why?
|
| Cold Temperature | 1 | 2007 | 40 | 0.250 |
Why?
|
| Methamphetamine | 1 | 2008 | 166 | 0.250 |
Why?
|
| Frail Elderly | 2 | 2007 | 18 | 0.250 |
Why?
|
| Lymphatic Metastasis | 5 | 2011 | 81 | 0.250 |
Why?
|
| Confidence Intervals | 4 | 2013 | 162 | 0.250 |
Why?
|
| Shoulder Joint | 1 | 2006 | 4 | 0.250 |
Why?
|
| Joint Diseases | 1 | 2006 | 5 | 0.250 |
Why?
|
| Coronary Artery Disease | 1 | 2008 | 163 | 0.250 |
Why?
|
| Myocardial Infarction | 2 | 2007 | 247 | 0.250 |
Why?
|
| Lymph Node Excision | 2 | 2006 | 25 | 0.240 |
Why?
|
| Biological Transport | 3 | 2021 | 204 | 0.240 |
Why?
|
| Respiratory Physiological Phenomena | 1 | 2006 | 12 | 0.240 |
Why?
|
| Diet | 2 | 2009 | 826 | 0.240 |
Why?
|
| Photobleaching | 1 | 2005 | 3 | 0.240 |
Why?
|
| Gastrointestinal Diseases | 1 | 2006 | 51 | 0.240 |
Why?
|
| Respiratory System | 1 | 2006 | 31 | 0.240 |
Why?
|
| Population Dynamics | 2 | 2012 | 50 | 0.240 |
Why?
|
| Cytokines | 1 | 2009 | 678 | 0.240 |
Why?
|
| Radiotherapy, Adjuvant | 4 | 2008 | 24 | 0.230 |
Why?
|
| Palmitates | 1 | 2005 | 15 | 0.230 |
Why?
|
| Golgi Apparatus | 1 | 2005 | 27 | 0.230 |
Why?
|
| Forecasting | 4 | 2013 | 136 | 0.230 |
Why?
|
| Curriculum | 2 | 2007 | 318 | 0.230 |
Why?
|
| Social Behavior | 2 | 2020 | 161 | 0.230 |
Why?
|
| Goserelin | 1 | 2005 | 1 | 0.230 |
Why?
|
| Inflammation | 2 | 2009 | 758 | 0.230 |
Why?
|
| Delirium | 1 | 2005 | 11 | 0.230 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2007 | 163 | 0.230 |
Why?
|
| Patient Compliance | 2 | 2003 | 233 | 0.230 |
Why?
|
| Fatigue | 1 | 2006 | 100 | 0.230 |
Why?
|
| Weight Gain | 1 | 2006 | 139 | 0.230 |
Why?
|
| Young Adult | 5 | 2019 | 5080 | 0.230 |
Why?
|
| Language | 2 | 2008 | 185 | 0.230 |
Why?
|
| Organizational Policy | 1 | 2025 | 25 | 0.230 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2005 | 31 | 0.220 |
Why?
|
| Tape Recording | 1 | 2024 | 11 | 0.220 |
Why?
|
| Data Interpretation, Statistical | 3 | 2019 | 125 | 0.220 |
Why?
|
| Coronary Thrombosis | 1 | 2024 | 7 | 0.220 |
Why?
|
| Hypercholesterolemia | 1 | 2005 | 42 | 0.220 |
Why?
|
| Linear Models | 4 | 2013 | 317 | 0.220 |
Why?
|
| Ischemic Attack, Transient | 1 | 2024 | 22 | 0.220 |
Why?
|
| Liver Neoplasms | 1 | 2007 | 224 | 0.220 |
Why?
|
| Glipizide | 2 | 2014 | 5 | 0.220 |
Why?
|
| Glyburide | 2 | 2014 | 9 | 0.220 |
Why?
|
| Focal Adhesions | 1 | 2014 | 16 | 0.220 |
Why?
|
| Hemorrhage | 1 | 2024 | 55 | 0.220 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2006 | 134 | 0.210 |
Why?
|
| Myocardial Ischemia | 1 | 2005 | 83 | 0.210 |
Why?
|
| Arthritis | 1 | 2004 | 18 | 0.210 |
Why?
|
| Thrombosis | 1 | 2024 | 81 | 0.210 |
Why?
|
| Models, Theoretical | 1 | 2005 | 232 | 0.210 |
Why?
|
| Health Care Surveys | 3 | 2011 | 152 | 0.200 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2017 | 1124 | 0.200 |
Why?
|
| Drug Therapy | 1 | 2003 | 17 | 0.200 |
Why?
|
| Body Weight | 1 | 2005 | 429 | 0.200 |
Why?
|
| Feasibility Studies | 1 | 2024 | 259 | 0.200 |
Why?
|
| Cholesterol | 1 | 2005 | 232 | 0.200 |
Why?
|
| Case Management | 1 | 2003 | 24 | 0.200 |
Why?
|
| Polypharmacy | 2 | 2014 | 27 | 0.200 |
Why?
|
| Office Visits | 3 | 2016 | 28 | 0.200 |
Why?
|
| Pressure Ulcer | 1 | 2023 | 6 | 0.200 |
Why?
|
| alpha-Synuclein | 2 | 2015 | 61 | 0.200 |
Why?
|
| Health Expenditures | 2 | 2016 | 44 | 0.200 |
Why?
|
| Histones | 1 | 2014 | 197 | 0.200 |
Why?
|
| Pain | 3 | 2020 | 290 | 0.200 |
Why?
|
| Health Surveys | 3 | 2012 | 405 | 0.190 |
Why?
|
| Intraoperative Care | 2 | 2013 | 13 | 0.190 |
Why?
|
| Medical Record Linkage | 1 | 2002 | 17 | 0.190 |
Why?
|
| Mastectomy, Segmental | 2 | 2002 | 25 | 0.190 |
Why?
|
| Morbidity | 2 | 2014 | 97 | 0.190 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2003 | 92 | 0.190 |
Why?
|
| Perception | 2 | 2018 | 215 | 0.190 |
Why?
|
| Obesity | 2 | 2010 | 1151 | 0.190 |
Why?
|
| Communication | 2 | 2017 | 210 | 0.190 |
Why?
|
| Wit and Humor as Topic | 1 | 2002 | 2 | 0.190 |
Why?
|
| Affect | 1 | 2004 | 180 | 0.190 |
Why?
|
| Geography | 2 | 2018 | 110 | 0.180 |
Why?
|
| Schools, Medical | 1 | 2004 | 208 | 0.180 |
Why?
|
| Nutrition Surveys | 3 | 2009 | 263 | 0.180 |
Why?
|
| Animals | 14 | 2021 | 16992 | 0.180 |
Why?
|
| Hallucinations | 1 | 2021 | 11 | 0.180 |
Why?
|
| Academic Medical Centers | 1 | 2002 | 76 | 0.180 |
Why?
|
| Insulin | 1 | 2003 | 258 | 0.180 |
Why?
|
| COS Cells | 3 | 2005 | 68 | 0.170 |
Why?
|
| Social Support | 2 | 2007 | 445 | 0.170 |
Why?
|
| HIV-1 | 3 | 2014 | 755 | 0.170 |
Why?
|
| Combined Modality Therapy | 2 | 2014 | 173 | 0.170 |
Why?
|
| Protein Transport | 5 | 2014 | 296 | 0.170 |
Why?
|
| Aggression | 1 | 2021 | 102 | 0.170 |
Why?
|
| Longevity | 2 | 2017 | 173 | 0.170 |
Why?
|
| Emotions | 2 | 2002 | 254 | 0.160 |
Why?
|
| Protein Multimerization | 1 | 2021 | 115 | 0.160 |
Why?
|
| Patient Selection | 2 | 2013 | 205 | 0.160 |
Why?
|
| Recurrence | 2 | 2017 | 152 | 0.160 |
Why?
|
| Hot Temperature | 1 | 2020 | 141 | 0.160 |
Why?
|
| Occupational Exposure | 1 | 2020 | 91 | 0.160 |
Why?
|
| Mediastinoscopy | 1 | 2019 | 1 | 0.160 |
Why?
|
| Thoracoscopy | 1 | 2019 | 4 | 0.160 |
Why?
|
| Thoracotomy | 1 | 2019 | 5 | 0.160 |
Why?
|
| Chi-Square Distribution | 2 | 2011 | 236 | 0.150 |
Why?
|
| Injections, Intravenous | 2 | 2010 | 67 | 0.150 |
Why?
|
| Radiation Dosage | 1 | 2019 | 37 | 0.150 |
Why?
|
| Exercise Test | 2 | 2013 | 74 | 0.150 |
Why?
|
| Policy Making | 2 | 2017 | 35 | 0.150 |
Why?
|
| Cell Line | 5 | 2015 | 1410 | 0.150 |
Why?
|
| Norepinephrine | 1 | 2009 | 97 | 0.150 |
Why?
|
| Gene Expression | 2 | 2021 | 701 | 0.150 |
Why?
|
| Stress, Physiological | 1 | 2020 | 172 | 0.150 |
Why?
|
| Microtubules | 2 | 2013 | 121 | 0.150 |
Why?
|
| Parkinsonian Disorders | 1 | 2009 | 42 | 0.150 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 83 | 0.150 |
Why?
|
| Decision Support Techniques | 1 | 2019 | 49 | 0.150 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 88 | 0.150 |
Why?
|
| Ascorbic Acid | 2 | 2009 | 74 | 0.150 |
Why?
|
| Child | 5 | 2020 | 3443 | 0.150 |
Why?
|
| Serotonin | 1 | 2009 | 123 | 0.140 |
Why?
|
| Latin America | 3 | 2010 | 55 | 0.140 |
Why?
|
| Health Services Needs and Demand | 2 | 2012 | 154 | 0.140 |
Why?
|
| Recovery of Function | 3 | 2021 | 107 | 0.140 |
Why?
|
| Prescriptions | 1 | 2018 | 19 | 0.140 |
Why?
|
| Local Government | 1 | 2018 | 15 | 0.140 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2018 | 2 | 0.140 |
Why?
|
| Pneumonectomy | 1 | 2018 | 10 | 0.140 |
Why?
|
| Cautery | 1 | 2017 | 1 | 0.140 |
Why?
|
| Foam Cells | 2 | 2008 | 16 | 0.140 |
Why?
|
| Diabetic Nephropathies | 3 | 2015 | 78 | 0.140 |
Why?
|
| Blood Pressure Determination | 1 | 2018 | 54 | 0.140 |
Why?
|
| Receptors, CXCR4 | 2 | 2008 | 74 | 0.140 |
Why?
|
| Critical Care | 1 | 2018 | 49 | 0.140 |
Why?
|
| Public Opinion | 2 | 2008 | 20 | 0.140 |
Why?
|
| Information Dissemination | 1 | 2018 | 66 | 0.130 |
Why?
|
| Endocytosis | 3 | 2013 | 118 | 0.130 |
Why?
|
| Models, Organizational | 1 | 2017 | 35 | 0.130 |
Why?
|
| Eligibility Determination | 1 | 2017 | 9 | 0.130 |
Why?
|
| Drug Combinations | 1 | 2017 | 104 | 0.130 |
Why?
|
| Elder Abuse | 2 | 2007 | 4 | 0.130 |
Why?
|
| Cerebral Cortex | 1 | 2009 | 306 | 0.130 |
Why?
|
| Censuses | 2 | 2009 | 28 | 0.130 |
Why?
|
| Research | 2 | 2011 | 181 | 0.130 |
Why?
|
| Disease Management | 1 | 2017 | 70 | 0.130 |
Why?
|
| Selenium | 2 | 2009 | 155 | 0.130 |
Why?
|
| Transport Vesicles | 2 | 2014 | 22 | 0.130 |
Why?
|
| Apolipoproteins E | 2 | 2008 | 138 | 0.130 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2017 | 75 | 0.130 |
Why?
|
| Patient Preference | 1 | 2017 | 60 | 0.130 |
Why?
|
| Neurons | 3 | 2021 | 1263 | 0.130 |
Why?
|
| Hypogonadism | 1 | 2016 | 23 | 0.120 |
Why?
|
| Virus Internalization | 2 | 2014 | 36 | 0.120 |
Why?
|
| Motor Skills | 1 | 2016 | 46 | 0.120 |
Why?
|
| Analysis of Variance | 2 | 2008 | 575 | 0.120 |
Why?
|
| Algorithms | 3 | 2009 | 509 | 0.120 |
Why?
|
| Prospective Payment System | 2 | 2008 | 8 | 0.120 |
Why?
|
| Cholelithiasis | 1 | 2015 | 5 | 0.120 |
Why?
|
| Sex Distribution | 2 | 2013 | 224 | 0.120 |
Why?
|
| Diffusion | 2 | 2005 | 63 | 0.120 |
Why?
|
| Diabetic Angiopathies | 2 | 2007 | 26 | 0.120 |
Why?
|
| Bacteroidaceae Infections | 1 | 2015 | 7 | 0.110 |
Why?
|
| Nomograms | 1 | 2015 | 14 | 0.110 |
Why?
|
| Health Facilities | 1 | 2015 | 32 | 0.110 |
Why?
|
| Burns | 1 | 2015 | 10 | 0.110 |
Why?
|
| National Institutes of Health (U.S.) | 2 | 2008 | 120 | 0.110 |
Why?
|
| Research Design | 2 | 2008 | 385 | 0.110 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2015 | 17 | 0.110 |
Why?
|
| Patient Care Planning | 1 | 2015 | 18 | 0.110 |
Why?
|
| Lumbar Vertebrae | 1 | 2015 | 44 | 0.110 |
Why?
|
| Clarithromycin | 1 | 2014 | 9 | 0.110 |
Why?
|
| Ciprofloxacin | 1 | 2014 | 16 | 0.110 |
Why?
|
| Home Care Services | 1 | 2015 | 37 | 0.110 |
Why?
|
| World Health Organization | 1 | 2014 | 36 | 0.110 |
Why?
|
| Green Fluorescent Proteins | 2 | 2005 | 209 | 0.110 |
Why?
|
| Health Priorities | 1 | 2014 | 25 | 0.110 |
Why?
|
| Metronidazole | 1 | 2014 | 16 | 0.110 |
Why?
|
| Fimbriae, Bacterial | 1 | 2014 | 30 | 0.110 |
Why?
|
| Sensitivity and Specificity | 3 | 2006 | 611 | 0.110 |
Why?
|
| Gait | 2 | 2012 | 27 | 0.110 |
Why?
|
| Axilla | 2 | 2006 | 6 | 0.110 |
Why?
|
| Diabetic Retinopathy | 2 | 2007 | 78 | 0.110 |
Why?
|
| Breast | 1 | 2015 | 139 | 0.100 |
Why?
|
| Uropathogenic Escherichia coli | 1 | 2013 | 8 | 0.100 |
Why?
|
| Complement System Proteins | 1 | 2013 | 25 | 0.100 |
Why?
|
| New Mexico | 2 | 2004 | 37 | 0.100 |
Why?
|
| Likelihood Functions | 1 | 2013 | 62 | 0.100 |
Why?
|
| Pharmacoepidemiology | 1 | 2013 | 1 | 0.100 |
Why?
|
| Drug Utilization Review | 1 | 2013 | 7 | 0.100 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2013 | 19 | 0.100 |
Why?
|
| Data Mining | 1 | 2013 | 30 | 0.100 |
Why?
|
| Mexico | 2 | 2006 | 298 | 0.100 |
Why?
|
| Biofilms | 1 | 2015 | 184 | 0.100 |
Why?
|
| Preoperative Care | 1 | 2013 | 32 | 0.100 |
Why?
|
| Women's Health | 2 | 2005 | 160 | 0.100 |
Why?
|
| Selection Bias | 2 | 2013 | 13 | 0.100 |
Why?
|
| Infant, Newborn | 2 | 2006 | 972 | 0.100 |
Why?
|
| Glucose Metabolism Disorders | 1 | 2012 | 4 | 0.090 |
Why?
|
| Medically Underserved Area | 1 | 2013 | 120 | 0.090 |
Why?
|
| Smoking Cessation | 1 | 2019 | 590 | 0.090 |
Why?
|
| Case-Control Studies | 2 | 2015 | 1285 | 0.090 |
Why?
|
| Infant | 2 | 2006 | 1175 | 0.090 |
Why?
|
| Patch-Clamp Techniques | 2 | 2011 | 228 | 0.090 |
Why?
|
| Confusion | 1 | 2011 | 5 | 0.090 |
Why?
|
| Institutionalization | 1 | 2011 | 2 | 0.090 |
Why?
|
| Anecdotes as Topic | 1 | 2011 | 6 | 0.090 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2011 | 14 | 0.090 |
Why?
|
| Chemokine CXCL12 | 2 | 2008 | 32 | 0.090 |
Why?
|
| Infusions, Intravenous | 1 | 2011 | 53 | 0.090 |
Why?
|
| Folic Acid | 2 | 2009 | 49 | 0.090 |
Why?
|
| Cost Allocation | 1 | 2011 | 4 | 0.090 |
Why?
|
| Qualitative Research | 1 | 2015 | 574 | 0.090 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2013 | 92 | 0.090 |
Why?
|
| Contractile Proteins | 1 | 2011 | 7 | 0.090 |
Why?
|
| False Negative Reactions | 1 | 2011 | 10 | 0.090 |
Why?
|
| Fungal Proteins | 2 | 2003 | 142 | 0.090 |
Why?
|
| Chlorides | 1 | 2011 | 59 | 0.090 |
Why?
|
| Disease-Free Survival | 1 | 2011 | 116 | 0.090 |
Why?
|
| C-Reactive Protein | 2 | 2009 | 167 | 0.090 |
Why?
|
| Child, Preschool | 2 | 2006 | 1546 | 0.090 |
Why?
|
| Insurance Claim Reporting | 1 | 2011 | 5 | 0.090 |
Why?
|
| Medicare Part A | 1 | 2011 | 3 | 0.090 |
Why?
|
| Locomotion | 1 | 2012 | 105 | 0.090 |
Why?
|
| Microfilament Proteins | 1 | 2011 | 72 | 0.090 |
Why?
|
| Virus Assembly | 1 | 2011 | 44 | 0.090 |
Why?
|
| Least-Squares Analysis | 1 | 2011 | 45 | 0.090 |
Why?
|
| Transforming Growth Factor beta3 | 1 | 2011 | 7 | 0.090 |
Why?
|
| Calcitriol | 1 | 2011 | 32 | 0.080 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 259 | 0.080 |
Why?
|
| Cholesterol, LDL | 2 | 2015 | 73 | 0.080 |
Why?
|
| Medicare Part B | 1 | 2011 | 16 | 0.080 |
Why?
|
| Tachycardia, Supraventricular | 1 | 2010 | 3 | 0.080 |
Why?
|
| Geographic Information Systems | 1 | 2011 | 47 | 0.080 |
Why?
|
| Attitude of Health Personnel | 1 | 2013 | 231 | 0.080 |
Why?
|
| Syndrome | 2 | 2012 | 73 | 0.080 |
Why?
|
| Nuclear Proteins | 1 | 2013 | 333 | 0.080 |
Why?
|
| Acute Disease | 1 | 2010 | 155 | 0.080 |
Why?
|
| Retinal Diseases | 1 | 2010 | 20 | 0.080 |
Why?
|
| Prisoners | 1 | 2012 | 102 | 0.080 |
Why?
|
| Motor Activity | 1 | 2013 | 437 | 0.080 |
Why?
|
| Psychotic Disorders | 1 | 2011 | 71 | 0.080 |
Why?
|
| Autoimmune Diseases | 1 | 2010 | 65 | 0.080 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2009 | 15 | 0.080 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2009 | 37 | 0.080 |
Why?
|
| Uterine Neoplasms | 1 | 2011 | 53 | 0.080 |
Why?
|
| Thyroid Neoplasms | 1 | 2010 | 50 | 0.080 |
Why?
|
| Task Performance and Analysis | 1 | 2009 | 47 | 0.080 |
Why?
|
| Vitamin D | 2 | 2009 | 196 | 0.080 |
Why?
|
| Antibody Formation | 1 | 2009 | 76 | 0.080 |
Why?
|
| Leiomyoma | 1 | 2011 | 42 | 0.080 |
Why?
|
| Hela Cells | 4 | 2014 | 376 | 0.080 |
Why?
|
| Cricetulus | 3 | 2015 | 82 | 0.080 |
Why?
|
| Attitude to Health | 3 | 2008 | 338 | 0.080 |
Why?
|
| CHO Cells | 3 | 2015 | 123 | 0.080 |
Why?
|
| Causality | 2 | 2007 | 45 | 0.080 |
Why?
|
| Bone and Bones | 2 | 2007 | 114 | 0.080 |
Why?
|
| Lower Extremity | 1 | 2009 | 38 | 0.080 |
Why?
|
| Carcinoma | 1 | 2010 | 108 | 0.080 |
Why?
|
| Immunity, Cellular | 1 | 2009 | 74 | 0.080 |
Why?
|
| Muscle Strength | 1 | 2009 | 37 | 0.080 |
Why?
|
| Adenoma | 1 | 2010 | 96 | 0.080 |
Why?
|
| Small-Area Analysis | 1 | 2009 | 10 | 0.070 |
Why?
|
| Poverty Areas | 2 | 2011 | 47 | 0.070 |
Why?
|
| Age Distribution | 3 | 2010 | 249 | 0.070 |
Why?
|
| False Positive Reactions | 2 | 2006 | 28 | 0.070 |
Why?
|
| Fibronectins | 2 | 2014 | 69 | 0.070 |
Why?
|
| Interleukin-6 | 1 | 2009 | 165 | 0.070 |
Why?
|
| Vitamin E | 1 | 2009 | 62 | 0.070 |
Why?
|
| Pilot Projects | 1 | 2011 | 760 | 0.070 |
Why?
|
| Carotenoids | 1 | 2009 | 74 | 0.070 |
Why?
|
| Critical Illness | 1 | 2009 | 47 | 0.070 |
Why?
|
| Social Medicine | 1 | 2008 | 4 | 0.070 |
Why?
|
| Ubiquitination | 1 | 2008 | 62 | 0.070 |
Why?
|
| Luminescent Proteins | 1 | 2008 | 68 | 0.070 |
Why?
|
| Accidents | 1 | 2008 | 6 | 0.070 |
Why?
|
| Treatment Refusal | 1 | 2008 | 23 | 0.070 |
Why?
|
| Apolipoprotein B-48 | 1 | 2008 | 7 | 0.070 |
Why?
|
| Progressive Patient Care | 1 | 2008 | 1 | 0.070 |
Why?
|
| 2-Aminopurine | 1 | 2008 | 10 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2008 | 108 | 0.070 |
Why?
|
| Tretinoin | 1 | 2008 | 50 | 0.070 |
Why?
|
| Eukaryotic Initiation Factor-2 | 1 | 2008 | 18 | 0.070 |
Why?
|
| Macrophages, Peritoneal | 1 | 2008 | 23 | 0.070 |
Why?
|
| Cardiovascular Agents | 1 | 2008 | 24 | 0.070 |
Why?
|
| Coronary Restenosis | 1 | 2008 | 28 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2008 | 105 | 0.070 |
Why?
|
| Prosthesis Design | 1 | 2008 | 47 | 0.070 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2008 | 57 | 0.070 |
Why?
|
| Observer Variation | 2 | 2006 | 59 | 0.070 |
Why?
|
| Palliative Care | 2 | 2012 | 61 | 0.070 |
Why?
|
| Memory Disorders | 1 | 2008 | 77 | 0.070 |
Why?
|
| Transfection | 2 | 2008 | 532 | 0.070 |
Why?
|
| Plectin | 1 | 2007 | 1 | 0.070 |
Why?
|
| Lymph Nodes | 1 | 2008 | 74 | 0.070 |
Why?
|
| Food | 1 | 2009 | 103 | 0.070 |
Why?
|
| Cell Nucleus | 2 | 2014 | 383 | 0.070 |
Why?
|
| Nucleus Accumbens | 1 | 2008 | 100 | 0.070 |
Why?
|
| Prostatectomy | 1 | 2008 | 70 | 0.070 |
Why?
|
| National Health Programs | 1 | 2007 | 20 | 0.070 |
Why?
|
| Hospital Planning | 1 | 2007 | 1 | 0.070 |
Why?
|
| Rural Population | 2 | 2017 | 373 | 0.070 |
Why?
|
| Hydrolases | 1 | 2007 | 15 | 0.070 |
Why?
|
| Sirolimus | 1 | 2008 | 70 | 0.070 |
Why?
|
| Health Care Reform | 1 | 2007 | 36 | 0.070 |
Why?
|
| Receptors, Glutamate | 1 | 2007 | 28 | 0.070 |
Why?
|
| Imidazoles | 1 | 2008 | 142 | 0.070 |
Why?
|
| Canada | 1 | 2007 | 163 | 0.070 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2007 | 51 | 0.070 |
Why?
|
| Carcinoma, Papillary | 1 | 2007 | 15 | 0.070 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2007 | 24 | 0.070 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2007 | 14 | 0.060 |
Why?
|
| Heating | 1 | 2007 | 6 | 0.060 |
Why?
|
| Community Health Nursing | 1 | 2007 | 14 | 0.060 |
Why?
|
| Climate | 1 | 2007 | 22 | 0.060 |
Why?
|
| Social Environment | 2 | 2008 | 218 | 0.060 |
Why?
|
| Lysosomes | 1 | 2007 | 86 | 0.060 |
Why?
|
| Oxidative Stress | 1 | 2013 | 1003 | 0.060 |
Why?
|
| General Surgery | 1 | 2007 | 28 | 0.060 |
Why?
|
| Forms and Records Control | 1 | 2006 | 6 | 0.060 |
Why?
|
| Models, Psychological | 1 | 2007 | 140 | 0.060 |
Why?
|
| Societies, Medical | 1 | 2007 | 74 | 0.060 |
Why?
|
| Resource Allocation | 1 | 2006 | 14 | 0.060 |
Why?
|
| Community Health Planning | 1 | 2007 | 38 | 0.060 |
Why?
|
| Europe | 1 | 2007 | 115 | 0.060 |
Why?
|
| Lipid Metabolism | 1 | 2008 | 148 | 0.060 |
Why?
|
| Quality Control | 1 | 2006 | 42 | 0.060 |
Why?
|
| Public Policy | 1 | 2006 | 36 | 0.060 |
Why?
|
| Endoscopy | 1 | 2006 | 17 | 0.060 |
Why?
|
| Radiology | 1 | 2006 | 12 | 0.060 |
Why?
|
| Schizophyllum | 2 | 2003 | 2 | 0.060 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2006 | 31 | 0.060 |
Why?
|
| West Indies | 1 | 2006 | 13 | 0.060 |
Why?
|
| Adaptation, Psychological | 1 | 2009 | 420 | 0.060 |
Why?
|
| Consensus Development Conferences, NIH as Topic | 2 | 2003 | 3 | 0.060 |
Why?
|
| Range of Motion, Articular | 1 | 2006 | 37 | 0.060 |
Why?
|
| Drug Approval | 1 | 2006 | 10 | 0.060 |
Why?
|
| United States Food and Drug Administration | 1 | 2006 | 29 | 0.060 |
Why?
|
| Benzo(a)pyrene | 1 | 2007 | 128 | 0.060 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2007 | 67 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 1 | 2006 | 61 | 0.060 |
Why?
|
| Cells, Cultured | 4 | 2015 | 1621 | 0.060 |
Why?
|
| Neuronal Plasticity | 1 | 2007 | 126 | 0.060 |
Why?
|
| Epidemiologic Methods | 1 | 2006 | 56 | 0.060 |
Why?
|
| Congresses as Topic | 1 | 2006 | 50 | 0.060 |
Why?
|
| Calcium | 1 | 2008 | 491 | 0.060 |
Why?
|
| Environmental Exposure | 1 | 2008 | 256 | 0.060 |
Why?
|
| Nutritional Status | 1 | 2006 | 119 | 0.060 |
Why?
|
| Nocodazole | 1 | 2005 | 8 | 0.060 |
Why?
|
| Medical Records | 1 | 2005 | 48 | 0.060 |
Why?
|
| Cycloheximide | 1 | 2005 | 30 | 0.060 |
Why?
|
| Paclitaxel | 1 | 2006 | 64 | 0.060 |
Why?
|
| Concept Formation | 1 | 2005 | 25 | 0.060 |
Why?
|
| Health Status Disparities | 2 | 2011 | 719 | 0.060 |
Why?
|
| Fertility Agents, Female | 1 | 2005 | 8 | 0.060 |
Why?
|
| Viscosity | 1 | 2005 | 46 | 0.060 |
Why?
|
| Health Behavior | 1 | 2009 | 575 | 0.060 |
Why?
|
| Databases as Topic | 1 | 2005 | 25 | 0.060 |
Why?
|
| Motion | 1 | 2005 | 31 | 0.060 |
Why?
|
| Cytosol | 1 | 2005 | 97 | 0.060 |
Why?
|
| HIV Infections | 2 | 2011 | 2586 | 0.060 |
Why?
|
| Anticholesteremic Agents | 1 | 2005 | 25 | 0.060 |
Why?
|
| Environmental Monitoring | 1 | 2007 | 230 | 0.060 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2011 | 968 | 0.060 |
Why?
|
| Polysaccharide-Lyases | 1 | 2014 | 10 | 0.060 |
Why?
|
| Sphygmomanometers | 1 | 2004 | 2 | 0.050 |
Why?
|
| Endoplasmic Reticulum | 1 | 2005 | 108 | 0.050 |
Why?
|
| Circadian Rhythm | 1 | 2007 | 236 | 0.050 |
Why?
|
| Heparin | 1 | 2014 | 40 | 0.050 |
Why?
|
| Environmental Pollutants | 1 | 2007 | 201 | 0.050 |
Why?
|
| Systole | 1 | 2004 | 67 | 0.050 |
Why?
|
| Diastole | 1 | 2004 | 47 | 0.050 |
Why?
|
| Laminin | 1 | 2014 | 58 | 0.050 |
Why?
|
| Keratinocytes | 2 | 2015 | 67 | 0.050 |
Why?
|
| Proteoglycans | 1 | 2014 | 49 | 0.050 |
Why?
|
| Fluorescence Resonance Energy Transfer | 2 | 2015 | 56 | 0.050 |
Why?
|
| Bone Density | 1 | 2005 | 103 | 0.050 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2005 | 89 | 0.050 |
Why?
|
| Managed Care Programs | 1 | 2004 | 40 | 0.050 |
Why?
|
| Cytoplasm | 1 | 2014 | 154 | 0.050 |
Why?
|
| Heart | 1 | 2005 | 184 | 0.050 |
Why?
|
| Cultural Characteristics | 1 | 2004 | 128 | 0.050 |
Why?
|
| Sociology | 1 | 2003 | 2 | 0.050 |
Why?
|
| Rats | 2 | 2008 | 3735 | 0.050 |
Why?
|
| Bacterial Proteins | 1 | 2008 | 595 | 0.050 |
Why?
|
| Marriage | 1 | 2003 | 21 | 0.050 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2008 | 1766 | 0.050 |
Why?
|
| Mice | 5 | 2011 | 6644 | 0.050 |
Why?
|
| Cricetinae | 2 | 2015 | 241 | 0.050 |
Why?
|
| Self Administration | 1 | 2003 | 69 | 0.050 |
Why?
|
| Insurance Coverage | 1 | 2004 | 110 | 0.050 |
Why?
|
| Blotting, Western | 3 | 2011 | 883 | 0.050 |
Why?
|
| Macrophages | 1 | 2007 | 529 | 0.050 |
Why?
|
| Brain Ischemia | 2 | 2018 | 189 | 0.050 |
Why?
|
| Internet | 1 | 2024 | 236 | 0.050 |
Why?
|
| Blood Glucose | 2 | 2017 | 389 | 0.050 |
Why?
|
| Colorado | 1 | 2002 | 16 | 0.050 |
Why?
|
| Data Collection | 1 | 2003 | 210 | 0.050 |
Why?
|
| Menopause | 1 | 2003 | 64 | 0.050 |
Why?
|
| Epidemiologic Studies | 1 | 2002 | 33 | 0.050 |
Why?
|
| Down-Regulation | 3 | 2011 | 456 | 0.050 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2003 | 282 | 0.050 |
Why?
|
| Arizona | 1 | 2002 | 139 | 0.050 |
Why?
|
| Neurodegenerative Diseases | 2 | 2015 | 141 | 0.050 |
Why?
|
| Cell Line, Tumor | 2 | 2014 | 2676 | 0.050 |
Why?
|
| Urban Population | 1 | 2004 | 374 | 0.040 |
Why?
|
| Mutation | 1 | 2005 | 1177 | 0.040 |
Why?
|
| Signal Transduction | 2 | 2007 | 2157 | 0.040 |
Why?
|
| 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine | 1 | 2009 | 15 | 0.040 |
Why?
|
| Denervation | 1 | 2009 | 27 | 0.040 |
Why?
|
| Protein Structure, Tertiary | 2 | 2013 | 423 | 0.040 |
Why?
|
| Models, Statistical | 2 | 2013 | 195 | 0.040 |
Why?
|
| Brain | 3 | 2015 | 1472 | 0.040 |
Why?
|
| Reimbursement, Incentive | 1 | 2019 | 12 | 0.040 |
Why?
|
| Cell Count | 1 | 2009 | 145 | 0.040 |
Why?
|
| Episode of Care | 1 | 2018 | 1 | 0.040 |
Why?
|
| Arthroplasty, Replacement | 1 | 2018 | 7 | 0.040 |
Why?
|
| Peptide Fragments | 1 | 2001 | 307 | 0.040 |
Why?
|
| Sampling Studies | 1 | 2018 | 64 | 0.040 |
Why?
|
| Intracranial Hemorrhages | 1 | 2018 | 28 | 0.040 |
Why?
|
| Chemotaxis | 2 | 2008 | 68 | 0.030 |
Why?
|
| Pamphlets | 1 | 2018 | 27 | 0.030 |
Why?
|
| Population Surveillance | 2 | 2011 | 246 | 0.030 |
Why?
|
| Fluorescent Dyes | 2 | 2011 | 182 | 0.030 |
Why?
|
| Phosphorylation | 2 | 2011 | 986 | 0.030 |
Why?
|
| Radiography, Thoracic | 1 | 2016 | 12 | 0.030 |
Why?
|
| Insurance Benefits | 1 | 2016 | 3 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2016 | 20 | 0.030 |
Why?
|
| Cell Movement | 2 | 2011 | 655 | 0.030 |
Why?
|
| Synucleins | 1 | 2015 | 7 | 0.030 |
Why?
|
| Biotinylation | 1 | 2015 | 12 | 0.030 |
Why?
|
| Membrane Microdomains | 1 | 2015 | 53 | 0.030 |
Why?
|
| Vision Screening | 1 | 2015 | 21 | 0.030 |
Why?
|
| Gene Transfer, Horizontal | 1 | 2015 | 24 | 0.030 |
Why?
|
| Genes, Bacterial | 1 | 2015 | 91 | 0.030 |
Why?
|
| Fimbriae Proteins | 1 | 2014 | 25 | 0.030 |
Why?
|
| Ghana | 1 | 2014 | 36 | 0.030 |
Why?
|
| Synaptic Transmission | 1 | 2015 | 149 | 0.030 |
Why?
|
| Virus Cultivation | 1 | 2014 | 7 | 0.030 |
Why?
|
| Virus Attachment | 1 | 2014 | 4 | 0.030 |
Why?
|
| Bacteriological Techniques | 1 | 2014 | 15 | 0.030 |
Why?
|
| Cell Transformation, Viral | 1 | 2014 | 24 | 0.030 |
Why?
|
| Mice, Knockout | 2 | 2008 | 1035 | 0.030 |
Why?
|
| Periodontitis | 1 | 2015 | 62 | 0.030 |
Why?
|
| Microbial Interactions | 1 | 2014 | 11 | 0.030 |
Why?
|
| Adhesins, Escherichia coli | 1 | 2013 | 3 | 0.030 |
Why?
|
| Virion | 1 | 2014 | 75 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2009 | 1869 | 0.030 |
Why?
|
| Spirometry | 1 | 2013 | 40 | 0.030 |
Why?
|
| Mutant Proteins | 1 | 2013 | 51 | 0.030 |
Why?
|
| Endosonography | 1 | 2013 | 6 | 0.030 |
Why?
|
| Cell Culture Techniques | 1 | 2014 | 152 | 0.030 |
Why?
|
| Microscopy, Electron | 1 | 2013 | 210 | 0.030 |
Why?
|
| Intranuclear Inclusion Bodies | 1 | 2013 | 3 | 0.030 |
Why?
|
| Fibroblasts | 1 | 2015 | 281 | 0.020 |
Why?
|
| Host-Pathogen Interactions | 1 | 2015 | 209 | 0.020 |
Why?
|
| Hep G2 Cells | 1 | 2013 | 63 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2013 | 148 | 0.020 |
Why?
|
| Cost Control | 1 | 2012 | 9 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2013 | 416 | 0.020 |
Why?
|
| Hospital Units | 1 | 2012 | 4 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2013 | 256 | 0.020 |
Why?
|
| Benzothiazoles | 2 | 2003 | 26 | 0.020 |
Why?
|
| Proteomics | 1 | 2014 | 378 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2011 | 33 | 0.020 |
Why?
|
| Annexins | 1 | 2011 | 6 | 0.020 |
Why?
|
| Thiazoles | 2 | 2003 | 76 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2012 | 123 | 0.020 |
Why?
|
| beta-Cyclodextrins | 1 | 2011 | 35 | 0.020 |
Why?
|
| gag Gene Products, Human Immunodeficiency Virus | 1 | 2011 | 19 | 0.020 |
Why?
|
| Clathrin | 1 | 2011 | 21 | 0.020 |
Why?
|
| Two-Hybrid System Techniques | 1 | 2011 | 51 | 0.020 |
Why?
|
| Gene Library | 1 | 2011 | 62 | 0.020 |
Why?
|
| Spectrometry, Fluorescence | 2 | 2003 | 184 | 0.020 |
Why?
|
| Smad Proteins | 1 | 2011 | 12 | 0.020 |
Why?
|
| Monitoring, Ambulatory | 1 | 2010 | 13 | 0.020 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2011 | 23 | 0.020 |
Why?
|
| Ergometry | 1 | 2010 | 7 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 2011 | 95 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2014 | 434 | 0.020 |
Why?
|
| Thyroidectomy | 1 | 2010 | 10 | 0.020 |
Why?
|
| Vulnerable Populations | 1 | 2012 | 166 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2011 | 127 | 0.020 |
Why?
|
| Markov Chains | 1 | 2010 | 43 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2011 | 411 | 0.020 |
Why?
|
| Fibrosis | 1 | 2011 | 169 | 0.020 |
Why?
|
| Caribbean Region | 1 | 2010 | 79 | 0.020 |
Why?
|
| Visual Fields | 1 | 2010 | 76 | 0.020 |
Why?
|
| Visual Acuity | 1 | 2010 | 111 | 0.020 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2011 | 199 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2010 | 94 | 0.020 |
Why?
|
| Postural Balance | 1 | 2009 | 37 | 0.020 |
Why?
|
| Independent Living | 1 | 2009 | 47 | 0.020 |
Why?
|
| Cerebral Hemorrhage | 1 | 2010 | 104 | 0.020 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoprotein U | 1 | 2008 | 1 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase 5 | 1 | 2008 | 9 | 0.020 |
Why?
|
| Presenilin-1 | 1 | 2008 | 28 | 0.020 |
Why?
|
| Insurance, Hospitalization | 1 | 2008 | 1 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2008 | 127 | 0.020 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2008 | 75 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2010 | 306 | 0.020 |
Why?
|
| Organizational Objectives | 1 | 2008 | 33 | 0.020 |
Why?
|
| Interdisciplinary Communication | 1 | 2008 | 40 | 0.020 |
Why?
|
| Maze Learning | 1 | 2008 | 113 | 0.020 |
Why?
|
| Amyloid beta-Protein Precursor | 1 | 2008 | 95 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2011 | 536 | 0.020 |
Why?
|
| Interinstitutional Relations | 1 | 2008 | 51 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2013 | 735 | 0.020 |
Why?
|
| Research Support as Topic | 1 | 2008 | 89 | 0.020 |
Why?
|
| Reaction Time | 1 | 2008 | 157 | 0.020 |
Why?
|
| Receptor, IGF Type 2 | 1 | 2007 | 7 | 0.020 |
Why?
|
| Jurkat Cells | 1 | 2007 | 87 | 0.020 |
Why?
|
| Geriatric Psychiatry | 1 | 2007 | 1 | 0.020 |
Why?
|
| Mental Status Schedule | 1 | 2007 | 18 | 0.020 |
Why?
|
| Macromolecular Substances | 1 | 2007 | 92 | 0.020 |
Why?
|
| Self Medication | 1 | 2007 | 13 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2007 | 98 | 0.020 |
Why?
|
| Protein Binding | 1 | 2011 | 1082 | 0.020 |
Why?
|
| Receptors, AMPA | 1 | 2007 | 58 | 0.020 |
Why?
|
| Herpesvirus 4, Human | 1 | 2007 | 36 | 0.020 |
Why?
|
| Electrophysiology | 1 | 2007 | 138 | 0.020 |
Why?
|
| Genes, Viral | 1 | 2007 | 61 | 0.020 |
Why?
|
| Osteocalcin | 1 | 2006 | 5 | 0.020 |
Why?
|
| Calcium Signaling | 1 | 2007 | 107 | 0.020 |
Why?
|
| Homocysteine | 1 | 2006 | 21 | 0.020 |
Why?
|
| Disease Progression | 1 | 2009 | 667 | 0.020 |
Why?
|
| Calcifediol | 1 | 2006 | 17 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2007 | 296 | 0.020 |
Why?
|
| Cytomegalovirus | 1 | 2007 | 45 | 0.020 |
Why?
|
| RNA Interference | 1 | 2007 | 247 | 0.020 |
Why?
|
| Astrocytes | 1 | 2008 | 244 | 0.020 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2007 | 135 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2008 | 665 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2006 | 113 | 0.020 |
Why?
|
| Psychomotor Performance | 1 | 2007 | 159 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2008 | 269 | 0.020 |
Why?
|
| Kidney | 1 | 2008 | 372 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 1 | 2008 | 386 | 0.020 |
Why?
|
| Vitamins | 1 | 2006 | 81 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2007 | 457 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2007 | 290 | 0.010 |
Why?
|
| Behavior, Animal | 1 | 2008 | 373 | 0.010 |
Why?
|
| Erythrocytes | 1 | 2006 | 126 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2007 | 694 | 0.010 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2007 | 184 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 652 | 0.010 |
Why?
|
| RNA, Viral | 1 | 2007 | 321 | 0.010 |
Why?
|
| Viral Proteins | 1 | 2007 | 190 | 0.010 |
Why?
|
| DNA, Viral | 1 | 2007 | 311 | 0.010 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2007 | 192 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2007 | 934 | 0.010 |
Why?
|
| Iron | 1 | 2006 | 251 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 2006 | 258 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2007 | 1180 | 0.010 |
Why?
|
| Centrifugation, Density Gradient | 1 | 2003 | 18 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2008 | 1070 | 0.010 |
Why?
|
| Microscopy, Atomic Force | 1 | 2003 | 61 | 0.010 |
Why?
|
| Current Procedural Terminology | 1 | 2002 | 1 | 0.010 |
Why?
|
| Fluorescence | 1 | 2003 | 118 | 0.010 |
Why?
|
| Biomedical Research | 1 | 2008 | 502 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2008 | 1596 | 0.010 |
Why?
|
| Minority Groups | 1 | 2008 | 690 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2007 | 1271 | 0.010 |
Why?
|
| North Carolina | 1 | 2002 | 127 | 0.010 |
Why?
|
| Pregnancy | 1 | 2007 | 1772 | 0.010 |
Why?
|
| Congo Red | 1 | 2001 | 4 | 0.010 |
Why?
|
| Spectrophotometry | 1 | 2001 | 63 | 0.010 |
Why?
|
| Serum Albumin, Bovine | 1 | 2001 | 49 | 0.010 |
Why?
|
| Protein Structure, Secondary | 1 | 2001 | 182 | 0.010 |
Why?
|
| Cattle | 1 | 2001 | 498 | 0.010 |
Why?
|
| Mental Health | 1 | 2002 | 385 | 0.010 |
Why?
|
| Smoking | 1 | 2002 | 1024 | 0.010 |
Why?
|